MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
It has come to our notice a news 'Marksans is said to be in talks with Moderna Inc for possible partnership to treat COVID 19' circulating through WhatsApp. Please be informed that the above news is absolutely false and baseless. This is for your information and dissemination to the members. MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
In continuation to our letter datd 1st June, 2020 in connection with the caption subject, please be informed that Marksans Pharma Limited has issued voluntary recall of one batch of Metformin Extended Release Tablets USP 500 mg (11279 bottles, Lot No. XP9004) due to detection of NDMA as a matter of abundant precaution. MARKSANS PHARMA LTD. - 524404 - Dividend
This is to inform you that the Board of Directors of the Company has, at its meeting held today i.e. Tuesday, 2nd June, 2020 at Mumbai, recommended dividend of Rs. 0.10 (Rupees Zero and Paise Ten) i.e. 10% per equity share of Re. 1/- each face value for the financial year ended 31st March, 2020, subject to approval of the shareholders in the ensuing Annual General Meeting. MARKSANS PHARMA LTD. - 524404 - Investors Presentation
Attached pl find Investors Presentation for the year ended 31st March, 2020 MARKSANS PHARMA LTD. - 524404 - News Release Dated 2Nd June 2020
Attached pl find a News Release dated 2nd June, 2020 MARKSANS PHARMA LTD. - 524404 - Annual Audited Financial Results, Standalone And Consolidated For The Quarter And Year Ended 31St March, 2020.
In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Audited Financial Results (both Standalone and Consolidated) for the quarter and year ended 31st March, 2020 approved by the Board of Directors at its meeting held today i.e. 2nd June, 2020 along with Auditor's Reports thereon. The meeting commenced at 10:00 a.m. and concluded at 11:00 a.m. In this connection, we hereby confirm that the Statutory Auditors have given their reports on the Audited Annual Financial Results for the financial year ended 31st March, 2020 (both Standalone and Consolidated) with unmodified opinion. MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
We have received communication from USFDA regarding verification of NDMA in Metformin Extended Release Tablets. We have submitted our preliminary response to US FDA on the same and are further communicating with them. We will inform the Exchange on the update of our communication with agency as it progresses. For the last year ended 31% March 2020, our Exports to USA for the Metformin Extended Release Tablets were of USD 1.43 million only which constitutes less than 1% of our Consolidated Revenue. MARKSANS PHARMA LTD. - 524404 - Board to consider Dividend
Marksans Pharma Ltd has informed BSE that the Meeting of the Board of Directors of the Company will be held on June 02, 2020, to consider and approve the Annual Audited Financial Results of the Company (both Standalone and Consolidated) for the Financial Year ended March 31, 2020. The Board of Directors will also consider recommendation of dividend, if any, forthe Financial Year 2019-20.Further as per the Insider Trading Code of the Company, the Trading Window for dealing in Company's shares has been closed for the Company's insiders from April 01, 2020 and will remain closed till Forty-Eight hours after the announcement of the Financial Results on June 02, 2020.
